- AREAS OF RESEARCH
- GET CONNECTED
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.
Closest Location
Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.
Condition
Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Immune System Diseases, Janus Kinase Inhibitors
Sex
Male or Female
Age
12+ years